NO329558B1 - Anvendelse av benzazepin-N-eddiksyrederivater til fremstilling av farmasoytiske preparater for profylakse og/eller hjelpebehandling av hjerteskader, samt produkter som kombinasjonspreparater som inneholder slike forbindelser - Google Patents

Anvendelse av benzazepin-N-eddiksyrederivater til fremstilling av farmasoytiske preparater for profylakse og/eller hjelpebehandling av hjerteskader, samt produkter som kombinasjonspreparater som inneholder slike forbindelser Download PDF

Info

Publication number: NO329558B1
Authority: NO; Norway
Prior art keywords: group; compounds; formula; cardiotoxic; alkyl
Prior art date: 1999-07-13

Application number

NO20020132A

Other languages

English (en)

Norwegian (no)

Other versions

NO20020132L (no

NO20020132D0 (no

Inventor

Dirk Thormahlen

Harald Waldeck

Julius Gy Papp

Susanna Rozsa

Original Assignee

Solvay Pharm Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-07-13

Filing date

2002-01-11

Publication date

2010-11-15

2002-01-11 Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh

2002-01-11 Publication of NO20020132D0 publication Critical patent/NO20020132D0/no

2002-03-12 Publication of NO20020132L publication Critical patent/NO20020132L/no

2010-11-15 Publication of NO329558B1 publication Critical patent/NO329558B1/no

Links

150000001875 compounds Chemical class 0.000 title claims description 33
238000011282 treatment Methods 0.000 title claims description 20
238000002360 preparation method Methods 0.000 title claims description 12
239000000825 pharmaceutical preparation Substances 0.000 title claims description 10
238000011321 prophylaxis Methods 0.000 title claims description 8
230000003683 cardiac damage Effects 0.000 title claims description 6
NTQSYIWTDXTRGG-UHFFFAOYSA-N 2-(1-benzazepin-1-yl)acetic acid Chemical class OC(=O)CN1C=CC=CC2=CC=CC=C12 NTQSYIWTDXTRGG-UHFFFAOYSA-N 0.000 title description 5
239000000824 cytostatic agent Substances 0.000 claims description 29
230000001451 cardiotoxic effect Effects 0.000 claims description 19
230000000694 effects Effects 0.000 claims description 19
150000003839 salts Chemical class 0.000 claims description 18
231100000457 cardiotoxic Toxicity 0.000 claims description 17
230000001085 cytostatic effect Effects 0.000 claims description 15
150000002148 esters Chemical class 0.000 claims description 14
125000004432 carbon atom Chemical group C* 0.000 claims description 12
239000002253 acid Substances 0.000 claims description 11
150000007513 acids Chemical class 0.000 claims description 11
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
239000003242 anti bacterial agent Substances 0.000 claims description 8
229940088710 antibiotic agent Drugs 0.000 claims description 8
229940045799 anthracyclines and related substance Drugs 0.000 claims description 7
230000003115 biocidal effect Effects 0.000 claims description 7
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 6
-1 dioxolanylmethyl group Chemical group 0.000 claims description 6
229910052739 hydrogen Inorganic materials 0.000 claims description 6
239000001257 hydrogen Substances 0.000 claims description 6
238000002560 therapeutic procedure Methods 0.000 claims description 6
MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 claims description 5
238000002512 chemotherapy Methods 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
229910052736 halogen Inorganic materials 0.000 claims description 4
150000002367 halogens Chemical class 0.000 claims description 4
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 3
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 3
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 3
238000009098 adjuvant therapy Methods 0.000 claims description 3
201000011510 cancer Diseases 0.000 claims description 3
229960000975 daunorubicin Drugs 0.000 claims description 3
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 3
229960001904 epirubicin Drugs 0.000 claims description 3
229960001156 mitoxantrone Drugs 0.000 claims description 3
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 3
210000004165 myocardium Anatomy 0.000 claims description 3
WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical group C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 2
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 1
125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 58
239000000126 substance Substances 0.000 description 34
229940009456 adriamycin Drugs 0.000 description 29
238000012360 testing method Methods 0.000 description 27
241001465754 Metazoa Species 0.000 description 26
229940079593 drug Drugs 0.000 description 10
239000003814 drug Substances 0.000 description 10
238000000034 method Methods 0.000 description 10
230000006378 damage Effects 0.000 description 9
230000037396 body weight Effects 0.000 description 7
239000000902 placebo Substances 0.000 description 7
229940068196 placebo Drugs 0.000 description 7
230000003078 antioxidant effect Effects 0.000 description 6
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 6
102100023321 Ceruloplasmin Human genes 0.000 description 5
108010075016 Ceruloplasmin Proteins 0.000 description 5
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 5
241000700159 Rattus Species 0.000 description 5
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 5
229960002591 hydroxyproline Drugs 0.000 description 5
238000007634 remodeling Methods 0.000 description 5
239000000243 solution Substances 0.000 description 5
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 5
206010048610 Cardiotoxicity Diseases 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
241000124008 Mammalia Species 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
239000013543 active substance Substances 0.000 description 4
231100000259 cardiotoxicity Toxicity 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
239000003826 tablet Substances 0.000 description 4
125000002947 alkylene group Chemical group 0.000 description 3
230000002107 myocardial effect Effects 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
125000004043 oxo group Chemical group O=* 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
125000001424 substituent group Chemical group 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
206010007572 Cardiac hypertrophy Diseases 0.000 description 2
208000031229 Cardiomyopathies Diseases 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
206010028594 Myocardial fibrosis Diseases 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
229940087168 alpha tocopherol Drugs 0.000 description 2
150000001408 amides Chemical group 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
150000001991 dicarboxylic acids Chemical class 0.000 description 2
230000004761 fibrosis Effects 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
230000009931 harmful effect Effects 0.000 description 2
210000005003 heart tissue Anatomy 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
239000000203 mixture Substances 0.000 description 2
125000004433 nitrogen atom Chemical group N* 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
230000003449 preventive effect Effects 0.000 description 2
230000003244 pro-oxidative effect Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000010998 test method Methods 0.000 description 2
229960000984 tocofersolan Drugs 0.000 description 2
239000002076 α-tocopherol Substances 0.000 description 2
235000004835 α-tocopherol Nutrition 0.000 description 2
ZCXLTWVZYXBHJS-UHFFFAOYSA-N 1,2-benzoxazepine Chemical compound O1N=CC=CC2=CC=CC=C12 ZCXLTWVZYXBHJS-UHFFFAOYSA-N 0.000 description 1
DQFQCHIDRBIESA-UHFFFAOYSA-N 1-benzazepine Chemical compound N1C=CC=CC2=CC=CC=C12 DQFQCHIDRBIESA-UHFFFAOYSA-N 0.000 description 1
QJJDBWAEIBNZPQ-UHFFFAOYSA-N 2-(3h-1,2-benzothiazepin-2-yl)acetic acid Chemical class S1N(CC(=O)O)CC=CC2=CC=CC=C21 QJJDBWAEIBNZPQ-UHFFFAOYSA-N 0.000 description 1
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
241000220317 Rosa Species 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
125000004423 acyloxy group Chemical group 0.000 description 1
125000005042 acyloxymethyl group Chemical group 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
238000010171 animal model Methods 0.000 description 1
238000003556 assay Methods 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
230000009787 cardiac fibrosis Effects 0.000 description 1
230000003293 cardioprotective effect Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229940099112 cornstarch Drugs 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000001120 cytoprotective effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
150000001990 dicarboxylic acid derivatives Chemical class 0.000 description 1
150000005690 diesters Chemical class 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
230000009982 effect on human Effects 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000013003 healing agent Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
150000002431 hydrogen Chemical class 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
125000004998 naphthylethyl group Chemical group C1(=CC=CC2=CC=CC=C12)CC* 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000004792 oxidative damage Effects 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
230000035699 permeability Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000563 toxic property Toxicity 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
229960000641 zorubicin Drugs 0.000 description 1
FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Cardiology (AREA)
Immunology (AREA)
Toxicology (AREA)
Heart & Thoracic Surgery (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20020132A 1999-07-13 2002-01-11 Anvendelse av benzazepin-N-eddiksyrederivater til fremstilling av farmasoytiske preparater for profylakse og/eller hjelpebehandling av hjerteskader, samt produkter som kombinasjonspreparater som inneholder slike forbindelser NO329558B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19932555A DE19932555A1 (de)	1999-07-13	1999-07-13	Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen
PCT/EP2000/006525 WO2001003699A1 (de)	1999-07-13	2000-07-10	Arzneimittel mit protektiver wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische substanzen

Publications (3)

Publication Number	Publication Date
NO20020132D0 NO20020132D0 (no)	2002-01-11
NO20020132L NO20020132L (no)	2002-03-12
NO329558B1 true NO329558B1 (no)	2010-11-15

Family

ID=7914519

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20020132A NO329558B1 (no)	1999-07-13	2002-01-11	Anvendelse av benzazepin-N-eddiksyrederivater til fremstilling av farmasoytiske preparater for profylakse og/eller hjelpebehandling av hjerteskader, samt produkter som kombinasjonspreparater som inneholder slike forbindelser

Country Status (28)

Country	Link
US (1)	US6906059B2 (es)
EP (1)	EP1200095B1 (es)
JP (1)	JP4824235B2 (es)
KR (1)	KR100738940B1 (es)
CN (1)	CN1267099C (es)
AR (1)	AR024476A1 (es)
AT (1)	ATE306926T1 (es)
AU (1)	AU782733B2 (es)
BR (1)	BR0012442A (es)
CA (1)	CA2377904C (es)
CZ (1)	CZ299070B6 (es)
DE (2)	DE19932555A1 (es)
DK (1)	DK1200095T3 (es)
ES (1)	ES2246874T3 (es)
HK (1)	HK1049116B (es)
HU (1)	HUP0202424A3 (es)
IL (2)	IL147604A0 (es)
MX (1)	MXPA02000411A (es)
NO (1)	NO329558B1 (es)
NZ (1)	NZ517130A (es)
PL (1)	PL198723B1 (es)
RU (1)	RU2268727C2 (es)
SK (1)	SK286020B6 (es)
TR (1)	TR200200053T2 (es)
TW (1)	TWI280880B (es)
UA (1)	UA73134C2 (es)
WO (1)	WO2001003699A1 (es)
ZA (1)	ZA200200265B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19932555A1 (de) *	1999-07-13	2001-01-18	Solvay Pharm Gmbh	Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen
JP2004536063A (ja) *	2001-05-18	2004-12-02	ゾルファイ　ファーマスーティカルズ　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング	医薬の製造における組み合わせたｎｅｐ／ｍｐ−抑制活性を有する化合物の使用
EP1448567B1 (en) *	2001-09-10	2009-12-30	Tibotec Pharmaceuticals	Method for the preparation of hexahydro-furo 2,3-b furan-3-ol
CN100591689C (zh) *	2002-01-16	2010-02-24	索尔瓦药物有限公司	苯并氮杂环庚三烯化合物的固体盐及其在制备药物化合物中的应用
AR038681A1 (es) *	2002-02-14	2005-01-26	Solvay Pharm Bv	Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
US7262184B2 (en)	2003-09-26	2007-08-28	Solvay Pharmaceuticals Gmbh	Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7452875B2 (en)	2003-09-26	2008-11-18	Solvay Pharmaceuticals Gmbh	Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7427611B2 (en)	2003-09-26	2008-09-23	Solvay Pharmaceuticals Gmbh	Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
JP4824573B2 (ja)	2003-11-18	2011-11-30	ゾルファイファーマスーティカルズゲゼルシャフトミットベシュレンクテルハフツング	腎不全、腎疾患または腎障害、特に糖尿病患者におけるこれらの治療のための医薬組成物
US20050267124A1 (en) *	2004-05-14	2005-12-01	Solvay Pharmaceuticals Gmbh	Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors
US20050267072A1 (en) *	2004-05-14	2005-12-01	Solvay Pharmaceuticals Gmbh	Pharmaceutical compositions containing dually acting inhibitors of neutral endopeptidase for the treatment of sexual dysfunction
US20050288272A1 (en) *	2004-06-23	2005-12-29	Solvay Pharmaceuticals Gmbh	Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists
EP1827448A1 (en)	2004-12-15	2007-09-05	Solvay Pharmaceuticals GmbH	Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and hmg coa reductase inhibitors
US20060205625A1 (en) *	2005-02-18	2006-09-14	Solvay Pharmaceuticals Gmbh	Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics
NZ571465A (en) *	2006-02-27	2011-09-30	Targeted Molecular Diagnostics Llc	Compositions and methods for reducing cellular fat and for predicting cardiac toxicity and upon treatment with tyrosine kinase inhibitors
WO2007102171A2 (en) *	2006-03-07	2007-09-13	Panacea Biotec Ltd	Novel salts of 1h-1-benzazepine-1-acetic acid, their preparation and pharmaceutical composition
US20070292503A1 (en) *	2006-06-16	2007-12-20	Gorissen Henricus R	Oral pharmaceutical composition of poorly water-soluble active substance
US20070299054A1 (en) *	2006-06-22	2007-12-27	Rajesh Jain	Oral pharmaceutical composition of a poorly water-soluble active agent

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2850078A1 (de) *	1978-11-18	1980-05-29	Basf Ag	Aminopropanolderivate des 6-hydroxy-2,3,4,5-tetrahydro-1h-1- benzazepin-2-ons
ES2198418T3 (es) *	1993-07-21	2004-02-01	Yamanouchi Pharmaceutical Co. Ltd.	Derivado de la benzazepina de fusion y composicion farmaceutica que incluye este derivado.
DE19510566A1 (de) *	1995-03-23	1996-09-26	Kali Chemie Pharma Gmbh	Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19638020A1 (de) *	1996-09-18	1998-03-19	Solvay Pharm Gmbh	Die gastrointestinale Durchblutung fördernde Arzneimittel
US6544979B1 (en) *	1997-09-18	2003-04-08	Janssen Pharmaceuticals, N.V.	Fused imidazole derivatives for improving oral bioavailability of pharmaceutical agents
DE19906310A1 (de) *	1999-02-16	2000-08-17	Solvay Pharm Gmbh	Arzneimittel zur Behandlung von Bluthochdruck
DE19932555A1 (de) *	1999-07-13	2001-01-18	Solvay Pharm Gmbh	Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen

1999
- 1999-07-13 DE DE19932555A patent/DE19932555A1/de not_active Withdrawn
2000
- 2000-06-23 AR ARP000103183A patent/AR024476A1/es unknown
- 2000-07-05 TW TW089113263A patent/TWI280880B/zh active
- 2000-07-10 NZ NZ517130A patent/NZ517130A/en not_active IP Right Cessation
- 2000-07-10 BR BR0012442-7A patent/BR0012442A/pt not_active Application Discontinuation
- 2000-07-10 HU HU0202424A patent/HUP0202424A3/hu not_active Application Discontinuation
- 2000-07-10 CA CA002377904A patent/CA2377904C/en not_active Expired - Fee Related
- 2000-07-10 TR TR2002/00053T patent/TR200200053T2/xx unknown
- 2000-07-10 DE DE50011388T patent/DE50011388D1/de not_active Expired - Lifetime
- 2000-07-10 JP JP2001508979A patent/JP4824235B2/ja not_active Expired - Fee Related
- 2000-07-10 AT AT00947960T patent/ATE306926T1/de active
- 2000-07-10 KR KR1020027000361A patent/KR100738940B1/ko not_active Expired - Fee Related
- 2000-07-10 PL PL353012A patent/PL198723B1/pl not_active IP Right Cessation
- 2000-07-10 ES ES00947960T patent/ES2246874T3/es not_active Expired - Lifetime
- 2000-07-10 MX MXPA02000411A patent/MXPA02000411A/es active IP Right Grant
- 2000-07-10 HK HK03101159.2A patent/HK1049116B/zh not_active IP Right Cessation
- 2000-07-10 CZ CZ20020052A patent/CZ299070B6/cs not_active IP Right Cessation
- 2000-07-10 IL IL14760400A patent/IL147604A0/xx active IP Right Grant
- 2000-07-10 RU RU2002102709/15A patent/RU2268727C2/ru not_active IP Right Cessation
- 2000-07-10 CN CNB008102015A patent/CN1267099C/zh not_active Expired - Fee Related
- 2000-07-10 AU AU61572/00A patent/AU782733B2/en not_active Ceased
- 2000-07-10 WO PCT/EP2000/006525 patent/WO2001003699A1/de not_active Ceased
- 2000-07-10 SK SK14-2002A patent/SK286020B6/sk not_active IP Right Cessation
- 2000-07-10 DK DK00947960T patent/DK1200095T3/da active
- 2000-07-10 EP EP00947960A patent/EP1200095B1/de not_active Expired - Lifetime
- 2000-10-07 UA UA2002021058A patent/UA73134C2/uk unknown
2002
- 2002-01-11 ZA ZA200200265A patent/ZA200200265B/xx unknown
- 2002-01-11 NO NO20020132A patent/NO329558B1/no not_active IP Right Cessation
- 2002-01-13 IL IL147604A patent/IL147604A/en not_active IP Right Cessation
- 2002-01-14 US US10/043,268 patent/US6906059B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
HK1049116B (zh)	2006-12-08
CA2377904A1 (en)	2001-01-18
ATE306926T1 (de)	2005-11-15
NO20020132L (no)	2002-03-12
SK142002A3 (en)	2002-06-04
EP1200095A1 (de)	2002-05-02
DE19932555A1 (de)	2001-01-18
IL147604A0 (en)	2002-08-14
DK1200095T3 (da)	2005-11-14
RU2268727C2 (ru)	2006-01-27
AU6157200A (en)	2001-01-30
IL147604A (en)	2006-12-31
NZ517130A (en)	2004-10-29
TR200200053T2 (tr)	2002-05-21
ES2246874T3 (es)	2006-03-01
NO20020132D0 (no)	2002-01-11
US20030040512A1 (en)	2003-02-27
TWI280880B (en)	2007-05-11
WO2001003699A1 (de)	2001-01-18
CN1373666A (zh)	2002-10-09
DE50011388D1 (de)	2006-03-02
SK286020B6 (sk)	2008-01-07
JP4824235B2 (ja)	2011-11-30
US6906059B2 (en)	2005-06-14
PL353012A1 (en)	2003-10-06
ZA200200265B (en)	2003-03-26
CN1267099C (zh)	2006-08-02
AU782733B2 (en)	2005-08-25
PL198723B1 (pl)	2008-07-31
UA73134C2 (en)	2005-06-15
CZ200252A3 (cs)	2002-08-14
AR024476A1 (es)	2002-10-02
MXPA02000411A (es)	2002-07-02
HUP0202424A2 (hu)	2002-11-28
KR100738940B1 (ko)	2007-07-12
HUP0202424A3 (en)	2003-03-28
JP2003504336A (ja)	2003-02-04
BR0012442A (pt)	2002-04-02
HK1049116A1 (en)	2003-05-02
CZ299070B6 (cs)	2008-04-16
KR20020019514A (ko)	2002-03-12
EP1200095B1 (de)	2005-10-19
CA2377904C (en)	2009-03-24

Publication	Publication Date	Title
NO329558B1 (no)	2010-11-15	Anvendelse av benzazepin-N-eddiksyrederivater til fremstilling av farmasoytiske preparater for profylakse og/eller hjelpebehandling av hjerteskader, samt produkter som kombinasjonspreparater som inneholder slike forbindelser
KR100200467B1 (ko)	1999-06-15	콜레스테롤 저하제 및 ace 억제제로 이루어진 아테롬성 동맥경화증의 예방, 안정화 또는 경감용 조성물
CA2725047A1 (en)	2009-11-26	Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same
CZ301499B6 (cs)	2010-03-24	Lék pro lécbu vysokého krevního tlaku
KR19980081621A (ko)	1998-11-25	과민성 장 증후군의 증상을 치료하기 위한 엔케이-1 수용체 길항물질
WO2009117367A1 (en)	2009-09-24	Method for treating cancers having high glucose requirements employing an sglt2 inhibitor and compositions thereof
US4469690A (en)	1984-09-04	Synergistic compositions of renal dopaminergic agent and β-blocker
AU2006215583B2 (en)	2011-05-12	Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics
US9029334B2 (en)	2015-05-12	Pharmaceutical composition for prevention or treatment of bone diseases comprising spinasterol glucoside derivative
US8518895B2 (en)	2013-08-27	Method for treating hyponatremia employing an SGLT2 inhibitor and composition containing same
RU2481106C2 (ru)	2013-05-10	Комбинированная терапия, включающая ингибиторы sglt и ингибиторы dpp4
WO2013137382A1 (ja)	2013-09-19	骨代謝改善剤
David	2003	Oxcarbazepine, Top&mate, Zonisamide, and Levetiracetam: Potential Use in Neuropathic Pain
EP1671631A2 (en)	2006-06-21	Compositions for the treatment of chronic lymphocytic leukemia
HUT52384A (en)	1990-07-28	Process for producing pharmaceutical compositions comprising dianhydrohexitol acyl derivatives
IE54373B1 (en)	1989-09-13	Pharmaceutical compositions comprising, 7,8-dihydroxy-1(hydroxyphenyl)-2,3,4,5-tetrahydro-ih-3-benzanepine derivatives and a beta-adrenergic blocking compound
HK1113906A (en)	2008-10-17	Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics

Legal Events

Date	Code	Title	Description
2013-03-11	MM1K	Lapsed by not paying the annual fees